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Abstract: Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation 
in pathophysiological conditions such as myocardial infarction, ischemia, and stroke. Although 
there has been significant advancement in antiplatelet therapeutic approaches, aspirin still 
remains the gold standard treatment in the clinical setting. Limitations in safety, efficacy, and 
tolerability have precluded many of the antiplatelet inhibitors from use in patients. Unforeseen 
incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients 
have hampered the development of superior next generation antiplatelet therapies. The phar-
macokinetic and pharmacodynamic profiles have also limited the effectiveness of a number 
of antiplatelet inhibitors currently in use due to variability in metabolism, time to onset, and 
reversibility. A focused effort in the development of newer antiplatelet therapies to address some 
of these shortcomings has resulted in a significant number of potential antiplatelet drugs which 
target enzymes (phosphodiesterase, cyclooxygenase), receptors (purinergic, prostaglandins, 
protease-activated receptors, thromboxane), and glycoproteins (αIIbβ3, GPVI, vWF, GPIb) in 
the platelet. The validation and search for newer antiplatelet therapeutic approaches proven to 
be superior to aspirin is still ongoing and should yield a better pharmacodynamic profile with 
fewer untoward side-effects to what is currently in use today.
Keywords: platelet aggregation inhibitors, blood platelets, purinergic P2Y receptor antagonists, 
receptor, PAR-1, platelet glycoprotein GPIIb-IIIa, thrombosis
Introduction
Antiplatelet drugs are the cornerstone in treatment of cardiovascular diseases. Despite 
the significant decrease in morbidity and mortality due to the currently approved anti-
platelet drugs, recurrent ischemia, myocardial infarction (MI), and unwanted bleeding 
still occur. The majority of drugs in development have focused on targeting either 
surface receptors or enzymes in the platelet in order to protect against unwanted clot 
formation following initial platelet activation. The first target for antiplatelet therapy 
was cyclooxygenase-1 by aspirin. While newer approaches for containing platelet 
activity have been developed, the pharmacodynamics and pharmacoeconomics suggest 
that aspirin will continue to be a mainstay for platelet therapy in the years to come. 
Currently, a combination regimen of aspirin and clopidogrel is the standard of care 
for prevention of platelet activation, thrombosis, and stroke. Unfortunately many of 
the current antiplatelet drugs face limitations in their utility due to genetic differences 
in the ability to metabolize pro-drugs, such as is the case with clopidogrel, acquired 
allergic responses such as is seen with heparin and aspirin, and resistance as has been 
reported with aspirin (see Table 1). Additional limitations observed in the application 
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of currently approved antiplatelet drugs include a narrow 
therapeutic window and limited efficacy. An overview of 
the current Food and Drug Administration (FDA)-approved 
antiplatelet therapies as well as those in development will be 
discussed in this review.
P2Y receptor antagonists
The P2Y receptors are G-protein-coupled (GPCR) purinergic 
receptors belonging to the P2 family. Two receptors, P2Y
1
 
and P2Y
12
, are present in the platelet. P2Y
1
 is a G
q
 coupled 
GPCR, while P2Y
12
 is coupled to Gα
i2
. Activation of P2Y
1
 
signals phospholipase β, leading to DAG formation, calcium 
mobilization, and eventually PKC and CalDAG-GEF activa-
tion.1 In contrast, P2Y
12
 activation inhibits adenylyl cyclase, 
activates phosphoinositide 3-kinase,2 the small GTPase 
Rap1,3 and activation of αIIbβ3.4
Ticlopidine (Ticlid®; Roche, Basel, Switzerland) is a first 
generation thienopyridine that requires cytochrome P450 
(CYP) 1 A metabolism prior to exerting its irreversible antag-
onistic effects on platelet reactivity via the P2Y
12
 receptor.5 
Early experimental observations showed agonist-induced 
platelet aggregation was intermittently inhibited by ticlopi-
dine.6,7 Studies with ticlopidine, however, exhibit off-target 
effects mediated by the inhibition of intracellular calcium 
mobilization.8 Maximal inhibition of platelet aggregation 
is observed 3–5 days post administration of ticlopidine.9 
The delayed onset of antiplatelet effects is a consequence 
of metabolism of the pro-drug.6 Clinical trials (CATS and 
TASS studies) have shown ticlopidine to be more effective 
than aspirin alone,10,11 but exhibiting significant off-target 
effects including minor bleeding with hemorrhagic events 
observed in less than 1% of subjects studied. Additionally, 
ticlopidine-treated patients typically discontinue treatment 
due to a variety of secondary adverse events including diar-
rhea, skin rash, and neutropenia.10,12
Clopidogrel (Plavix®, Bristol-Myers Squibb, New York 
City, NY), a second generation oral thienopyridine, also 
requires metabolism of a pro-drug by the CYP2C19. The 
active metabolite, which is a highly labile compound, irre-
versibly binds to and inhibits the P2Y
12
 receptor through 
a disulfide bridge. The CURE trial has shown the clinical 
benefit of the dual clopidogrel-aspirin therapy compared with 
aspirin alone by significantly reducing mortality and nonfatal 
MI or stroke in patients with unstable angina; however, the 
dual regimen was associated with an increase in bleeding 
compared with placebo.13,14 The CAPRIE trial, which evalu-
ated the efficacy of clopidogrel monotherapy compared with 
dual therapy of clopidogrel plus aspirin, showed clopidogrel 
treatment results in a reduction of primary endpoints.15 
Evidence of poor metabolizers for clopidogrel has helped 
to explain the reduced function in patients with an altered 
CYP2C19 allele.16 Poor metabolizers of clopidogrel have 
diminished platelet inhibition resulting in a higher rate of 
adverse cardiovascular events than noncarriers.17
Table 1 Approved antiplatelet drugs
Drug Target Half-life Side effects Bioavailability Use
Ticlopidine 
(Ticlid)
P2Y12 receptor 12 hours Bleeding, rash, neutropenia, thrombotic 
thrombocytopenic purpura (rare), nausea, 
vomiting, heartburn, indigestion
Oral Transient ischemic 
attacks, patients 
undergoing PCi
Clopidogrel 
(Plavix)
P2Y12 receptor 6–8 hours Bleeding, rash, neutropenia, thrombotic 
thrombocytopenic purpura (rare)
Oral NSTEMi, STEMi, PCi, 
recent stroke, or 
established PAD
Prasugrel 
(Effient)
P2Y12 receptor 8 hours Bleeding Oral Patients with ACS 
undergoing PCi
Ticagrelor 
(Brilinta)
P2Y12 receptor 6–12 hours Dyspnea Oral STEMi, ACS
Abciximab 
(ReoPro)
GPiib-iiia , 10–30 minutes Bleeding, thrombocytopenia, EDTA-induced 
psuedothrombocytopenia
iv PCi
Eptifibatide 
(integrilin)
GPiib-iiia ∼2.5 hours Bleeding, thrombocytopenia, EDTA-induced 
psuedothrombocytopenia
iv NSTEMi, PCi, unstable 
angina
Tirofiban 
(Aggrastat)
GPiib-iiia 2 hours Bleeding, thrombocytopenia, EDTA-induced 
psuedothrombocytopenia
iv NSTEMi, PCi, unstable 
angina
Cilostazol 
(Pletal)
PDE3 11–13 hours Headache, dizziness, hypotension, flushing, 
nausea, vomiting, diarrhea, abdominal pain
Oral intermittent 
claudication, PAD, PCi
Dipyridamole 
(Aggrenox)
PDE3 and inhibition 
of adenosine uptake
10 hours Bleeding, headache, diarrhea, palpitations, 
dizziness, rash, pancytopenia
Oral Transient ischemic 
attacks
Abbreviations: ACS, acute coronary syndromes; EDTA, ethylenediaminetetraacetic acid; GP, glycoprotein; iv, intravenous; NSTEMi, non-ST elevation myocardial infarction; 
PAD, peripheral arterial disease; PCi, percutaneous coronary intervention; PDE, phosphodiesterase; STEMi, ST elevation myocardial infarction.
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Prasugrel (Effient®, Eli Lilly and Company, Indianapolis, 
IN) is a third-generation thienopyridine, chemically distinct 
from clopidogrel. In-vivo and in-vitro pharmacological 
studies have demonstrated that this adenosine triphosphate 
(ATP) analog selectively and irreversibly inhibits adenosine 
diphosphate (ADP)-induced aggregation to a greater degree 
than clopidogrel.18 The irreversible binding is thought to be 
due to the disulfide binding between the reactive thiol group 
of the active metabolite and the cysteine residue of the P2Y
12
 
receptor.19–21 Prasugrel is an orally available pro-drug that 
requires active transformation via the CYP450 along with 
esterases.22 Activation of the pro-drug requires CYP3 A4 
and CYP2B6.23 Clinical studies have verified that inhibi-
tion of platelet aggregation is more effective with prasugrel 
compared with clopidogrel after a single dose in healthy 
subjects.23 Furthermore, subjects who responded poorly to 
clopidogrel showed greater platelet-induced inhibition in 
response to prasugrel.23,24 Further, assessment of secondary 
endpoints favors prasugrel due to lower incidences of car-
diovascular death, nonfatal MI, and rehospitalization due to 
recurrent ischemia.
Ticagrelor (Brillinta®, AstraZeneca, London, UK), 
an oral cyclopentyl-triazolo-pyrimidine analog, unlike 
thienopyridines, is a direct and reversible inhibitor of 
the P2Y
12
 receptor that is activated from its pro-drug by 
CYP3 A.25 Ticagrelor exerts its action via binding to the 
P2Y
12
 receptor at a site distinct from the ADP binding site, 
thus making it an allosteric inhibitor.25 As a consequence of 
P2Y
12
 inhibition, ATP is converted to cyclic monophosphate, 
vasodilator-stimulated phospoprotein is dephosphorylated, 
and activation of PI3-K is inhibited.26 The PLATO trial 
compared ticagrelor with clopidogrel in which the primary 
composite endpoints, stroke, MI, cardiovascular death, and 
stent thrombosis, were reduced in patients with acute coro-
nary syndromes (ACS) (with or without ST-elevation MI).27 
The benefit of ticagrelor appears to be attenuated in patients 
with lower bodyweight and those not taking lipid-lowering 
drugs in North American groups relative to comparative 
studies elsewhere.28 There is no significant difference in 
major bleeding between the two agents; however, spontane-
ous (noncoronary artery bypass grafts) or nonprocedural-
related bleeding is increased with ticagrelor. Additionally, 
off-target effects of dyspnea and asymptomatic ventricular 
pauses are associated with ticagrelor use.28,29 In general, 
ticagrelor has so far proven superior to current treatment 
regimens, including a rapid onset of action, acceptable safety 
profile, and effectiveness in reducing the primary endpoints 
in ACS patients.
Elinogrel (PRT060128, Novartis, Basel, Switzerland/
Portola Pharmaceuticals, South San Francisco, CA) is a 
direct-acting reversible P2Y
12
 receptor inhibitor that is cur-
rently undergoing clinical investigation (INNOVATE-PCI) 
for efficacy and safety in patients undergoing percutaneous 
coronary intervention (PCI) (see Table 2).30 Preclinical data 
show that intravenous or orally administered elinogrel is 
superior to clopidogrel and has minimal effect on bleeding 
times.31 In addition, a single dose of elinogrel has been shown 
to overcome high platelet reactivity in patients undergoing 
PCI who were nonresponsive to clopidogrel.31 Elinogrel, 
while still in clinical development for safety and efficacy 
assessment in patients, shows promise as a next generation 
P2Y
12
 antagonist.
Cangrelor (ARC-69931MX, The Medicines Company, 
Parsippany, NJ) is an intravenous nontheinopyridine and 
reversible P2Y
12
 inhibitor. Like prasugrel and ticagrelor, 
cangrelor showed a more rapid onset of action and greater 
degree of platelet inhibition than clopidogrel. Recent 
evaluations of the inhibitor in the CHAMPION-PCI and 
CHAMPION-PLATFORM trials were stopped early due to 
its lack of apparent differences in the primary endpoint of 
death, MI, or ischemia-driven revascularization 48 hours after 
PCI.32 Also, the rate of major bleeding in patients undergoing 
PCI was higher with cangrelor compared with clopidogrel 
in both studies.33
Table 2 Antiplatelet drugs under development
Drug Target Stage of development
Elinogrel P2Y12 receptor Phase ii
Cangrelor P2Y12 receptor Phase iii
BX 667 P2Y12 receptor Preclinical
vorapaxor (SXH 530348) PAR1 Phase iii
Atopaxar (E5555) PAR1 Phase ii
S18886 (Terutroban) TPα Phase iii
Z-335 TPα Phase i
BM-573 TPα Preclinical
h6B4-Fab GPib Preclinical
GPGP-290 GPibα Preclinical
SZ2 GPibα Preclinical
PR-15 (Revacept) GPvi Phase i completed
DZ-697b GPvi Phase i completed
AJW200 vWF Phase i
ARC1779 vWF Phase ii
ARC15105 vWF Preclinical
ALX-0081 vWF Phase ii
ALX-0681 vWF Phase ii
82D6 A3 vWF Preclinical
Z4 A5 GPiib-iiia Preclinical
DG-041 PGE2 Phase ii
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BX 667 is an orally active reversible P2Y
12
 receptor 
antagonist that is metabolized by esterases to form the 
carboxylic active form, BX 048.34 In-vitro, ADP-induced 
aggregation is potently inhibited by BX 667. Additionally, 
administration of BX 667 results in a rapid and sustained 
inhibition aggregation.35 This observation is also supported 
by the intravenous BX 048 and oral BX 667 administration in 
rat arteriovenous-shunt model which showed a similar phar-
macodynamic relationship between the plasma concentration 
of BX 048 and thrombus inhibition.34 This antagonist has yet 
to be evaluated in healthy human subjects.
Glycoprotein antagonists
αiibβ3 antagonists
Glycoprotein GPIIbIIIa (αIIbβ3) is the most abundant integ-
rin on the platelet surface.36 αIIbβ3 is known to be involved in 
both inside-out or outside-in platelet signaling. The inside-out 
signaling in platelet activation involves the various signaling 
pathways that converge into a common signaling endpoint 
that leads to the activation of integrin αIIbβ3.37 Ligand 
binding of fibrinogen or von Willebrand factor (Vwf) to 
αIIbβ3 mediates platelet adhesion and aggregation, triggers 
outside-in integrin activation and results in additional granule 
secretion, stabilization of platelet adhesion, aggregation, and 
clot retraction.37
Abciximab (ReoPro®; Eli Lilly) is an antibody devel-
oped from the murine human chimera c7E3 Fab, which 
targets the integrin αIIbβ3,38 preventing integrin binding 
to fibrinogen and Vwf. Abciximab rapidly binds with high 
affinity and has a slow rate of dissociation from its target.39 
In addition, abciximab binds with high affinity to α
v
β3 
(vitronectin receptor)40 and low affinity to the leukocyte 
MAC-1 receptor.41 Initial intravenous administration enables 
rapid onset of platelet inhibition.42 As abciximab has an 
extremely short half-life,43 platelet aggregation returns to 
baseline levels within 12–24 hours following discontinuation 
of therapy.44,45 Interestingly, the ISAR-REACT trial dem-
onstrated no additional benefit of abciximab over placebo 
in the reduction of ischemic complications or mortality.43,46 
Similarly, among diabetic patients without elevated troponin 
levels undergoing elective PCI, no difference was observed 
in primary endpoint events between abciximab and placebo/
clopidogrel groups.47 Conversely, in patients with elevated 
troponin levels, the incidence of mortality and recurrent 
ischemic complications was significantly reduced with 
abciximab.48 Careful monitoring must be accompanied with 
the administration of abciximab as bleeding and thrombo-
cytopenia have been observed.49–51
Eptifibatide (Integrilin®, Millenium Pharmaceuticals, 
Cambridge, MA/Schering-Plough, Kenilworth, NJ) is a 
cyclic heptapeptide derived from snake venom that contains 
a KGD (lysine-glycine-aspartic acid) sequence which selec-
tively recognizes αIIβ3.52 The IMPACT-II study showed that 
a single loading dose followed by continuous infusion for 
20–24 hours only resulted in 50% αIIbβ3 receptor block-
ade; thus, limited benefits and efficacy through eptifibatide 
were observed.53 The ESPRIT trial, however, which utilized 
intravenous administration of a double bolus54 followed by 
maintenance infusion, significantly reduced the 30 days 
incidence of death, MI, and target vessel revascularization,55 
establishing the clinical efficacy for this drug. These observa-
tions were confirmed in the PURSUIT trial, which showed 
an absolute reduction in the 30-day incidence of death and 
MI on eptifibatide.56 Despite the reduction in mortality, the 
ACUITY trial also showed an increase incidence of major 
bleeding in patients with ACS undergoing PCI.57,58
Tirofiban (Aggrastat®, Merck, Whitehouse Station, NJ) is 
a tyrosine-derivative nonpeptide mimetic reversible inhibitor 
of αIIbβ3 that specifically and competitively binds to the 
receptor. Treatment with tirofiban in combination with aspirin 
and heparin in patients with ACS significantly reduced the 
30-day post-treatment incidence of death, MI, or recurrent 
ischemia.59 Further, tirofiban was superior for ACS patients 
recovering from invasive coronary angiography.59 As for the 
use of tirofiban as an adjunct to PCI, tirofiban was shown 
to be inferior to abciximab in the RESTORE and TARGET 
trials where the incidence of composite death, nonfatal MI, 
and urgent target vessel revascularization were higher with 
tirofiban or abciximab at 30 days.60
Z4 A5 is a novel αIIbβ3 peptide antagonist that is currently 
in development. This antagonist has been shown to inhibit 
platelet-induced aggregation and thrombi formation. Addi-
tionally, when Z4 A5 was examined along with heparin and/
or aspirin in the rabbit arteriovenous shunt thrombosis model, 
it was shown to be an effective antithrombotic agent when 
administered with aspirin.61 The pharmacodynamics and phar-
macokinetics in humans are currently under investigation.61
Additional glycoprotein antagonists
Additional glycoprotein targets have received a fair amount 
of attention in the drive to develop novel approaches for 
antiplatelet intervention. The Vwf, a multimeric glycoprotein 
that acts as a bridging element between damaged endothelial 
sites and the glycoprotein receptors on platelets, is one such 
target. The A1 and A3 domains of Vwf bind to collagen, while 
the A1 domain is bound to the GPIb-IX-V platelet receptor 
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complex.62,63 Vwf also binds to active αIIbβ3 on the platelet 
surface. Interactions between αIIbβ3 and Vwf contribute 
to the final, irreversible binding of platelets to the suben-
dothelium and play a leading role in platelet aggregation.64 
A second target receiving attention as a potential site for 
antiplatelet therapy is the collagen receptor glycoprotein VI 
(GPVI). The collagen-GPVI interaction triggers subsequent 
tyrosine phosphorylation of the immunoreceptor tyrosine-
based activation motif of the Fc receptor γ chain, activating 
the Syk kinases pathway, LAT, SLP-76, and phospholipase 
Cγ2,65 resulting in platelet activation or aggregation.
vwf antagonists
AJW200 is an IgG4 humanized monoclonal antibody to Vwf 
which has been shown to specifically inhibit high-shear-
stress-induced platelet aggregation in a concentration-depen-
dent manner in vitro in blood from human volunteers.66
ARC1779 (Archemix Corp, San Francisco, CA) is an 
aptamer-based antagonist. This second generation nuclease-
resistant aptamer is conjugated to a 20-Kda polyethylene gly-
col and binds with high affinity to the active Vwf A1-domain 
and inhibits Vwf-dependent platelet aggregation.67 A Phase 
II trial demonstrated that continuous infusion of ARC1779 
effectively increased platelet counts in critically ill thrombotic 
thrombocytopenic purpura patients by preventing platelet 
aggregation and loss of platelets. Cessation of ARC1779 infu-
sion resulted in platelet count reduction and progression of 
thrombotic thrombocytopenic purpura-related organ dam-
age.68 This drug is currently under clinical investigation.
Other Vwf antagonists in clinical development or investi-
gations include ARC15105, ALX-0081 (Ablynx), ALX-0681, 
and 82D6 A3. ARC15105 is a chemically advanced aptamer 
with assumed higher affinity to Vwf, but less specific inhibi-
tor of Vwf-dependent platelet aggregation than ARC1779, 
based on ex-vivo trials.69 The preclinical and clinical trials 
have shown that ALX-0081, a bivalent humanized nanobody 
that recognizes the Glycoprotein Ib (GPIb) binding site of 
Vwf, is a potent and safe inhibitor of Vwf-mediate platelet 
aggregation over a wide range of doses when administered 
in combination with aspirin, heparin, and clopidogrel. ALX-
0081 is currently under investigation in PCI patients in a 
Phase II trial. 82D6 A3, a monoclonal antibody directed 
against amino acids Arg-963, Pro-981, Asp-1009, Arg-1016, 
Ser-1020, Met-1022, and His-1023 of the Vwf A3 domain,70 
was shown to result in complete inhibition of Vwf binding 
to collagen during the first 3 days after stent implantation 
in baboons.71 Further trials will need to follow to verify 
82D6 A3 efficacy, safety, and tolerability.
GPvi receptor antagonists
PR-15 (Revacept®, ABX-CRO/Medifacts GmbH, Goer-
litz, Saxony, Germany) is a soluble, dimeric glycoprotein 
(GPVI)-Fc that has been shown to adhere to exposed colla-
gen in endothelial lesions preventing the binding to platelet 
GPVI receptors. Collagen-induced human platelet adhesion 
or plaque formation were significantly reduced with pre-
treatment of soluble GPVI-Fc.72,73 Similarly, infusion of 
GPVI-Fc was shown to virtually abolish stable arrest and 
aggregation of platelets following vascular injury in mice.65 
Subsequently, a Phase I clinical trial demonstrated that intra-
venous administration of PR-15 is safe and well tolerated by 
healthy volunteers.74
DZ-697b is an orally active collagen and ristocetin inhibi-
tor. Safety and efficacy have been assessed in a Phase I trial 
which showed potential benefits such that bleeding time was 
substantially shortened compared with clopidogrel treat-
ment.75 DZ-697b is currently under clinical investigation.
GPib receptor antagonists
Novel targets still under investigation include h6B4-Fab, 
GPGP-290, and SZ2. h6B4-Fab is a murine monoclonal 
antibody, derived from the humanized Fab fragment of 6B4 
targeting GPIbα and neutralizes the binding site of the Vwf 
A1 domain.76,77 6B4 has been shown to inhibit platelet adhe-
sion by competing with Vwf for binding to GPIbα under 
high-shear conditions. Moreover, preliminary data show 6B4 
has no effect on platelet count or bleeding times in vivo in 
baboons, but dose- and time-dependently inhibited ristocetin-
induced platelet aggregation.78 GPG-290 is a recombinant, 
chimeric antibody purified from Chinese hamster ovary cell 
culture that contains the amino-terminal 290 amino acids 
of GPIbα linked to the human IgG1. GPG-290 treated dogs 
were shown to exhibit prolonged bleeding compared with 
the clopidogrel-treated control, despite the prevention of 
coronary artery thrombosis.79 SZ2, a monoclonal antibody 
developed against GPIbα, has also been shown to inhibit 
both ristocetin- and botrocetin-induced platelet aggregation 
in vitro.80 Preclinical investigations are still underway to 
determine the in-vivo efficacy of SZ2.
Phosphodiesterase antagonists
Platelets express three phosphodiesterase (PDE) isoenzymes, 
PDE 2, 3, and 5. PDEs regulate the levels of 3,5′-cyclic ade-
nosine monophosphate (Camp) and 3′,5′-cyclic guanosine 
monophosphate (Cgmp) by catalyzing the hydrolysis of 
Camp and Cgmp to inactive 5′-AMP and 5′-GMP, respec-
tively.81 Platelet activation relies on degradation of Camp 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
37
Approaches to antiplatelet therapy
Journal of Blood Medicine 2012:3
and Cgmp; hence regulating these secondary messengers 
is fundamental in regulating platelet activation and 
thrombosis.
Cilostazol (Pletal®, Otsuka Pharmaceutical Co, Tokyo, 
Kapan) is a type III PDE (PDE3) selective oral inhibitor.82 
Liu and colleagues have shown that cilostazol enhances the 
interstitial concentration of adenosine in several in-vitro 
and in-vivo models83 by inhibiting adenosine uptake. This 
in turn stimulates A
2
 receptors, which further increases 
Camp levels. As a result, platelet-induced aggregation is 
reversibly inhibited by cilostazol.84 Cilostazol is extensively 
metabolized by CYP3 A4, while CYP2C19 is also shown 
to have a minor role in cilostazol metabolism.85 Cilostazol 
is safe and effective in reducing the incidence of repeated 
revascularization after PCI and risk of restenosis; however, 
this drug does not show superiority in reducing the primary 
composite endpoints of adverse cardiovascular events after 
drug-elution stent implantation.86 Despite the functional 
implications of adjunctive treatment with cilostazol compared 
with standard aspirin and clopidogrel treatment, as shown in 
the OPTIMUS-2 study, the accompanied side effects (head-
aches, gastrointestinal symptoms, and skin rash) often lead 
to the discontinuation of the drug.87
Dipyridamole (Aggrenox®, Boehringer Ingelheim, 
Ingelheim, Germany) is a pyridopyrimidine derivative with 
both antiplatelet and vasodilator properties.88 Similar to 
cilostazol, dipyridamole inhibits cyclic nucleotide phos-
phodiesterase and blocks adenosine uptake, which results in 
increased Camp.89 The ESPS-2 and ESPRIT trials showed 
that dual treatment of dipyridamole and aspirin reduced risk 
of stroke or death by 37% compared with aspirin alone.90,91 
Based on the ESPRIT and ESPS-2 trials, dipyridamole has 
been FDA approved for stroke prevention.91
Thromboxane A2 receptor 
antagonists
Platelets express the thromboxane receptor α (TPα), a GPCR 
that is coupled to G
q
 and G
12/13
 and signals platelet activation 
through a number of intracellular pathways which converge 
to reinforce primary platelet activation through thrombin or 
collagen.92
S18886 (terutroban) is an oral reversible inhibitor of TPα. 
In preclinical studies, S18886 dose-dependently prolonged 
occlusive thrombus formation in animal models, but did not 
alter the size of the myocardial infarct size in the ischemia-
perfusion model. S18886 and clopidogrel were effective in 
preventing occlusive thrombus formation with a moderate 
increase in bleeding time.93 Subsequently, however, in the 
Phase III clinical trial (PERFORM), S18886 did not meet 
the predefined criteria for noninferiority since S18886 and 
aspirin had similar rates of protection without safety advan-
tages for S18886.94
Z-335 ((+/-)-sodium[2-(4-chlorophenylsulfonyl-amino-
methyl)indan-5-yl]acetate monohydrate) is an oral TPα 
antagonist that has previously been shown to dose-depend-
ently inhibit the specific binding of [3H]SQ-29548 (TPα 
inhibitor) to human and guinea pig platelet membranes.95 
In healthy male Japanese volunteers, Z-335 inhibited 
U46619-induced platelet aggregation within 2 hours of 
administration.96
BM-573, another investigational inhibitor that targets 
TPα, has been shown to halt the progression of atheroscle-
rosis in low-density lipoprotein receptor deficient mice.97 
Preclinical models have shown that arachidonic acid-induced 
aggregation is completely inhibited in the presence of 
BM-57398 and clinical studies on this compound are cur-
rently ongoing.
Thrombin receptor antagonists
Thrombin activates human platelets via two protease activated 
receptors (PARs), PAR1 and PAR4. PAR activation leads to 
a diverse range of pro-thrombotic signaling events mediated 
through G
q
, G
12/13
, and possibly G
i
, resulting in phospholipase 
β activation, Rho activation, and adenyl cyclase inhibition, 
respectively. PAR activation requires thrombin cleavage of the 
amino terminus of the receptor, revealing a tethered ligand. 
While it has been challenging to develop an inhibitor that 
can directly compete with the endogenous tethered ligand, 
development of PAR1 inhibitors as a therapeutic target to 
minimize uncontrolled platelet activation has recently been 
investigated.
SCH 530348 (Vorapaxar®, Merck and Co, Whitehouse 
Station, NJ) is an orally active synthetic analog of him-
bacine99 that competitively binds with high affinity to the 
PAR1. Previous in-vitro assays show SCH 530348 inhibited 
thrombin- and thrombin receptor activating peptide-induced 
platelet aggregation, without affecting the aggregation 
induced by ADP, U46619, or collagen. In addition, SCH 
530348 did not affect the prothrombin and activated partial 
thromboplastin time, suggesting that bleeding time may not 
be increased. Pre-clinically, cynomolgus monkeys treated 
with SCH 530348 alone or in addition with aspirin and 
clopidogrel, showed no increase in bleeding times.100 The 
TRA-PCI study verified that addition of SCH 530348 to 
standard antiplatelet therapy (aspirin and clopidogrel) was 
not associated with increases in thrombolysis in MI (TIMI) 
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or bleeding compared with the control group.101 The Phase III 
clinical trials TRA-CER and TRA 2ºP-TIMI, which sought 
to assess the impact of vorapaxar on cardiovascular death, 
MI, stroke, and recurrent vascular events in patients with 
established coronary, cerebral, or peripheral atherosclerosis102 
failed due to unforeseen intracranial bleeding.102
Preclinical trials showed that oral administration of the 
PAR1 antagonist, E5555 (Atopaxar®, Eisai Co Ltd, Tokyo, 
Japan), significantly prolonged bleeding times in guinea 
pigs.103 Further, PECAM-1, active αIIbβ3, GPIb, thrombo-
spondin, and vitronectin expression were significantly 
reduced by E5555 in whole blood flow cytometry. Clinical 
studies have shown that E5555 attenuated thrombin-induced 
but not ADP-induced platelet aggregation.104,105
Additional PAR-1 antagonists SCH 205831 and SCH 
602539 are still under investigation. Preliminary data show 
SCH 205831 derived from himbacine inhibited platelet depo-
sition in baboons with arteriovenous-shunt thrombosis. Simi-
larly, SCH 602539 inhibited thrombosis in a dose-dependent 
manner in the Folts model of thrombosis in anesthetized 
cynomolgus monkeys.106 These compounds continue to be 
developed in preclinical models.
Conclusion
Significant progress has been made in advancing our under-
standing of how platelet activation directly regulates throm-
bus formation in the vessel leading to occlusive thrombi and 
stroke. However, a continued need for the development of 
new antiplatelet therapies exists as the risk for MI, stroke, 
and death, remain a persistent problem for individuals suf-
fering from cardiovascular disease. Further, while aspirin 
continues to be the first line of pharmacological intervention 
in antiplatelet therapy, the risk of bleeding is significantly 
exacerbated by its irreversible action coupled to the addi-
tional regimen of dual therapy often employed to minimize 
thrombotic events. In hopes of reducing prolonged bleeding 
or myocardial infarct events, newer compounds continue to 
be developed to target alternative sites in the platelet. The 
successful implementation of these strategies may signifi-
cantly reduce the morbidity and mortality in cardiovascular 
disease due to unwanted platelet activation as well as exces-
sive bleeding due to traditional approaches. Even with the 
newer antiplatelet drugs entering the market in the near 
future, we are faced with the realization that activation of the 
platelet involves an increasingly complex signaling network. 
Hence, new frontiers will need to be explored which will 
take advantage of this signaling to reveal novel therapeutic 
targets with diminished off-target effects.
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